Growing Market for Smoking Cessation and Nicotine Withdrawal Products

Jul.19.2022
The smoking cessation market has grown with innovations in products and increased awareness of health risks, expected to reach $27.84 billion by 2031.

According to analysis of smoking cessation industry statistics from the past few decades by TMR market research company, the use of smoking cessation products to help smokers quit has increased, primarily including skin patches and oral products. The smoking cessation and nicotine withdrawal market is expected to reach $27.84 billion by 2031. The target audience is becoming more aware of the health burden associated with smoking, as smoking-related illnesses lead to premature deaths every year.


Innovative marketing campaigns that promote the availability and effectiveness of various smoking cessation products have raised awareness of the benefits of quitting smoking, leading to an expansion of the market for tobacco cessation and nicotine replacement companies. National research institutions in the United States and United Kingdom are heavily supporting research on tobacco-related diseases. Due to these factors and market trends, smoking cessation programs in Europe have seen significant growth, expanding the market for smoking cessation products.


A series of studies have emphasized the effectiveness of e-cigarettes in smoking cessation therapy, which has broadened the perspective of the smoking cessation and nicotine withdrawal market. Over the years, the number of young people seeking to quit smoking has significantly increased, which has expanded commercial avenues for gum, lozenges, inhalers, nasal sprays, and nicotine patches. The target audience's understanding of smoking cessation products through online channels has also been increasing, which has promoted the growth of the smoking cessation and nicotine withdrawal market.


The primary findings of the market research on smoking cessation and nicotine withdrawal.


Increased demand for both over-the-counter (OTC) and prescription products, including those designed to alleviate the health burdens of smoking and nicotine, is being driven by a focus on reducing smoking- and nicotine-related health issues. This demand has also spurred growth in the nicotine replacement therapy (NRT) market, which has become an effective tool for smoking cessation and nicotine addiction treatment. Over the past several decades, new smoking cessation aids have been introduced to the market, particularly in the US and UK. Notably, e-cigarettes play a crucial role in smoking cessation, with companies relying on advances in nicotine technology to convince smokers to successfully switch to vaping.


The widespread sales of nicotine replacement therapy (NRT) products driving income growth: For many years, NRT products have been widely adopted in key markets such as the United States. A business intelligence study by TMR found that NRT lozenges, patches, and gum have increased in commercialization in the smoking cessation and nicotine withdrawal market. Additionally, in 2020, NRT product sales saw significant growth in Europe and North America, driving market growth for smoking cessation and nicotine addiction treatment.


Smoking and Nicotine Cessation Market: Key Drivers


The increasing burden of health issues caused by tobacco and nicotine products is a key driver in the market. It is important to note that smoking-related illnesses lead to millions of premature deaths each year.


Electronic cigarettes are becoming increasingly popular and are beneficial for users who want to quit smoking. Their effectiveness is enhanced when used in conjunction with counseling, behavioral therapy, and medication. There is a growing market for smoking cessation products and nicotine replacement therapy (NRT) products that are expanding the avenues for quitting smoking and overcoming nicotine addiction.


In 2020, North America took a leading position in the global smoking cessation and nicotine withdrawal market, with the United States offering significant revenue opportunities for market participants.


Europe is another lucrative market region. Over the years, the implementation of anti-smoking initiatives in certain areas and the rapid adoption of nicotine-containing smoking cessation products have created a significant source of revenue.


The Asia-Pacific region is witnessing a colossal market, and noteworthy is the incredible untapped avenue that manufacturers of NRT (nicotine replacement therapy) products are discovering in the region.


I am sorry, I cannot do that as the original text in unclear. Please provide me with the text you want me to translate.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Kantar Study Finds More Than 93% of Vape Products in Ukraine Fail Regulatory Requirements
Kantar Study Finds More Than 93% of Vape Products in Ukraine Fail Regulatory Requirements
According to Interfax-Ukraine, a study conducted by market research firm Kantar Ukraine at the request of major tobacco companies found that more than 93% of vape products in Ukraine did not fully comply with regulatory requirements. The research examined product categories, brand distribution and consumer purchasing channels, showing that pod systems and disposable vapes represent major segments of the market, while offline retail remains the dominant purchasing channel. The findings highlight ongoing compliance challenges in Ukraine’s vape market.
Aug.26
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
At InterTabac 2026 in Dortmund, China Tobacco International (HK) Company Limited (CTIHK) is exhibiting across two separate booths in Hall 5 and Hall 4. Products observed by 2Firsts include heated tobacco products, nicotine pouches, Chinese cigars and tobacco leaf. Nicotine pouch products on display include TOOP, Shuangxi and Ashima.
Market
Sep.16
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22